Gardasil 9 Vaccine for Blood Cancers

Recruiting in Palo Alto (17 mi)

Overseen byJessica P. Hwang

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Waitlist Available

Sponsor: M.D. Anderson Cancer Center

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?This phase IV trial studies how well Gardasil 9 vaccine works in preventing human papillomavirus (HPV) infection in patients with hematologic malignancies who are undergoing donor stem cell transplant. Vaccines, such as Gardasil 9, may help the body build an effective immune response to kill cancer cells.

Eligibility Criteria

This trial is for English-speaking adults with blood cancers, who are 6-12 months post donor stem cell transplant and will receive usual vaccinations. It's not for those who've had prior transplants, pregnant women, have very low blood counts, a history of HPV-related cancer or previous HPV vaccination.

Inclusion Criteria

I am an English-speaking adult, 6-12 months post stem cell transplant for blood cancer at MD Anderson, getting standard vaccines.

Patients from approved protocol 2015-0795 will be invited to this vaccine study

Exclusion Criteria

I have had cancer linked to HPV before.

I tested positive for pregnancy before my stem cell transplant evaluation.

I have had a stem cell transplant from a donor.

+3 more

Participant Groups

The study tests the effectiveness of Gardasil 9 vaccine in preventing HPV infection among patients with hematologic malignancies after undergoing a donor stem cell transplant.

1Treatment groups

Experimental Treatment

Group I: Prevention (Gardasil 9 vaccine)Experimental Treatment1 Intervention

Patients undergo standard of care allogeneic stem cell transplant. 6-12 months following transplant, patients receive recombinant human papillomavirus nonavalent vaccine IM on day 0 and at 2 and 6 months in the absence of disease progression or unacceptable toxicity.